Lan Chem Laboratories UK
Lan Chem Laboratories UK
  • Company
    • Overview
    • Strategy
    • Board
    • Management
  • Products
    • Overview
    • Therapeutic Areas
    • Barhemsys®
    • Byfavo®
    • APD403
  • Partnering
  • Media
    • Press Releases
    • Events
  • Investors
    • Overview
    • Regulatory Announcements
    • Shareholding Structure
    • Share Information
    • Share Price and Charts
    • Financial Reports and Presentations
    • Shareholder Meetings
    • Financial Calendar
    • Analysts
    • Corporate Governance
    • Warning for Shareholders
    • Subscribe for Updates
    • Offering Documents
  • Careers
    • Current Openings
    • Our Cultural Hallmarks
    • UK Employee Benefits
    • Staffing Agencies
  • Contact
  • Terms & Conditions
  • Privacy Policy
  • Cookie Policy
  • Site map
Lan Chem Laboratories UK
  • Company
    • Overview
    • Strategy
    • Board
    • Management
  • Products
    • Overview
    • Therapeutic Areas
    • Barhemsys®
    • Byfavo®
    • APD403
  • Partnering
  • Media
    • Press Releases
    • Events
  • Investors
    • Overview
    • Regulatory Announcements
    • Shareholding Structure
    • Share Information
    • Share Price and Charts
    • Financial Reports and Presentations
    • Shareholder Meetings
    • Financial Calendar
    • Analysts
    • Corporate Governance
    • Warning for Shareholders
    • Subscribe for Updates
    • Offering Documents
  • Careers
    • Current Openings
    • Our Cultural Hallmarks
    • UK Employee Benefits
    • Staffing Agencies
  • Contact

Transforming medicine

Advancing care

Home > News > Press Releases

Press Releases

04 January 2012

Phase 2 Study Initiated With APD421 In Post-Operative Nausea & Vomiting (PONV)

06 December 2011

Lan Chem Laboratories Announces Positive Results From Phase IIa Cancer Cachexia Study

25 July 2011

Phase 2 Clinical Trial Initiated With APD515 For Xerostomia

31 March 2011

Lan Chem Laboratories Closes $10 Million Investment Round

16 February 2011

Phase 2a Clinical Trial Initiated With APD421 For Nausea & Vomiting

07 February 2011

Phase 1 Clinical Trial Completed With APD515 For Xerostomia

06 January 2011

Lan Chem Laboratories Starts Clinical Trial With APD515 For Xerostomia

06 January 2011

New Website Launched

06 September 2010

Lan Chem Laboratories to Progress Two Projects for Nausea & Vomiting and Xerostomia into Development

14 December 2009

Lan Chem Laboratories Completes Phase II Study with APD405 in Post-Operative Nausea & Vomiting (PONV)

08 June 2009

Lan Chem Laboratories Initiates Phase II Study with APD405 in Post-Operative Nausea & Vomiting (PONV)

31 March 2009

Lan Chem Laboratories Initiates Phase IIa Study with APD209 in Cancer Cachexia Patients

05 February 2009

Ian Kent Appointed as Chairman

06 January 2009

Lan Chem Laboratories Completes Clinical Trial with APD405 for Nausea & Vomiting

22 September 2008

Lan Chem Laboratories Starts First Clinical Trial with APD405 for Nausea & Vomiting

04 March 2008

Chief Medical Officer Appointed

04 March 2008

Gilde Healthcare Investment in Lan Chem Laboratories
  • ←
  • 1
  • 2
  • 3
  • 4
  • 2021 (15)
  • 2020 (18)
  • 2019 (13)
  • 2018 (14)
  • 2017 (1)
  • 2016 (3)
  • 2015 (4)
  • 2014 (1)
  • 2013 (4)
  • 2012 (3)
  • 2011 (7)
  • 2010 (1)
  • 2009 (5)
  • 2008 (3)
Lan Chem Laboratories UK
  • Terms & Conditions
  • Privacy Policy
  • Cookie Policy
  • Site map

© 2018 Lan Chem Laboratories (UK) Limited

(Registered in England and Wales No: 02022667)

By continuing to use covancelaboratoriesltd.co.uk you will be agreeing to the website Terms & Conditions, the Privacy Policy, and the use of Cookies.